Top Stories
Top Stories
Pharmaceuticals

SEC charges Bausch Health subsidiary Salix Pharmaceuticals with misleading investors 

Key Points
  • Salix Pharmaceuticals, a unit of Bausch Health Companies Inc, has moved to settle charges brought by the U.S. Securities and Exchange Commission
  • The company misled investors about the company's prospects, the SEC said on Friday.
The U.S. Securities and Exchange Commission in Washington, D.C.
Adam Jeffery | CNBC

Salix Pharmaceuticals, a unit of Bausch Health Companies, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

As part of the proposed settlement, which must be approved by a U.S. district court, Salix agreed to be enjoined from future violations of antifraud and corporate reporting provisions of federal securities laws, the agency said.

Next Article
Key Points
  • "Mad Money" host Jim Cramer sat down with Joe Papa, the new CEO of the controversial Valeant Pharmaceuticals, to catch up on the drug maker's turnaround.
  • Papa said his executive team has worked hard to reduce Valeant's debt, put pricing policies in place and make the stock more attractive to shareholders.
  • Papa also offered a response to the growing rift between business leaders and President Donald Trump.